New research builds on scientific understanding of how air pollution and cancer risk are distributed throughout the U.S. Air pollution, often resulting from industrial or vehicle emissions, can travel for hundreds of miles and impact the health of communities through higher rates of asthma, respiratory infections, stroke, and lung cancer. Although previous studies have identified disparities in how public health risks vary by income and race, a new study takes a detailed look across U.S. census tracts to find patterns in who is most at risk from cancer resulting from lifetime exposure to air pollution and how this risk is changing through time. 

This study highlights the effectiveness of proof-of-concept 1DZnO nanoplatforms for rapid cancer biomarker detection by examining the nanoscale integration of 1DZnO with these bioreceptors to deliver reliable photoluminescent output signals.

Tailored small molecules that bind to cancer-causing proteins and neutralize tumor cells—this is the specialty of Georg Winter, Principal Investigator at CeMM, who has established himself as a global leader in the field. His latest ERC CoG project proposal, GE|NEomorph, will take his research to a new level. Instead of marking cancer proteins for cellular degradation, as in previous approaches, Winter’s designer molecules now target transcription factors. These molecules aim to reprogram the genetic activity of cancer cells—a promising new strategy for developing innovative therapies. The European Research Council (ERC) agrees, awarding €1.9 million over the next five years to support this groundbreaking project.

The IRB Barcelona researcher is awarded €2 M to undertake the IGNITE Project over the next five years.

The study will explore how different inflammatory processes and epigenetic mechanisms influence the development and evolution of pancreatic cancer.

The findings could open new avenues for early diagnosis and the development of more efficient treatments.

A special protein can play a key role in the fight against certain types of prostate cancer. This is shown in a study by an international research group led from Umeå University, Sweden. Until now, treatments have involved blocking the protein in question that builds a so-called signalling pathway, but now the researchers show that by instead doing the opposite and activating the protein and signalling pathway, the cancer is counteracted.

A series of five papers, published today in The Lancet Oncology by a University of Pittsburgh-led international team, highlights critical public health challenges related to cancer control in the eight countries that form the South Asian Association for Regional Cooperation (SAARC) and the Rohingya refugee population in Bangladesh. The series underscores barriers contributing to significant disparities in cancer outcomes and identifies actionable solutions to address these challenges in one of the most comprehensive efforts to understand this region’s cancer burden.